146 related articles for article (PubMed ID: 32759397)
1. High expression of CD133 - stem cell marker for prediction of clinically agressive type of colorectal cancer.
Kostovski O; Antovic S; Trajkovski G; Kostovska I; Jovanovic R; Jankulovski N
Pol Przegl Chir; 2020 Apr; 92(3):9-14. PubMed ID: 32759397
[TBL] [Abstract][Full Text] [Related]
2. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
3. The role of "Prominin - 1" marker in adenomatous colorectal polyps.
Safiyeva A; Bayramov N; Avunduk M
Pol Przegl Chir; 2021 Nov; 94(2):19-26. PubMed ID: 35485315
[TBL] [Abstract][Full Text] [Related]
4. CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies.
Huang R; Mo D; Wu J; Ai H; Lu Y
Medicine (Baltimore); 2018 Jun; 97(23):e10446. PubMed ID: 29879012
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD133 is associated with poor prognosis in stage II colorectal carcinoma.
Park YY; An CH; Oh ST; Chang ED; Lee J
Medicine (Baltimore); 2019 Aug; 98(32):e16709. PubMed ID: 31393377
[TBL] [Abstract][Full Text] [Related]
6. Augmented CD133 expression in distal margin correlates with poor prognosis in colorectal cancer.
Pradhan T; Padmanabhan K; Prasad M; Chandramohan K; Nair SA
J Cell Mol Med; 2019 Jun; 23(6):3984-3994. PubMed ID: 30950180
[TBL] [Abstract][Full Text] [Related]
7. Malnutrition as an unfavorable prognostic factor after surgical treatment for metastatic colorectal cancer.
Skroński M; Olszewska N; Nyckowski P; Ukleja A; Lisowska J; Słodkowski M; Szczygieł B
Pol Przegl Chir; 2024 Mar; 96(3):1-8. PubMed ID: 38721641
[TBL] [Abstract][Full Text] [Related]
8. CD133 Expression at the Metastatic Site Predicts Patients' Outcome in Colorectal Cancer with Synchronous Liver Metastasis.
Kishikawa J; Kazama S; Oba K; Hasegawa K; Anzai H; Harada Y; Abe H; Matsusaka K; Hongo K; Oba M; Yasuda K; Otani K; Nishikawa T; Tanaka T; Tanaka J; Kiyomatsu T; Hata K; Kawai K; Nozawa H; Yamaguchi H; Ishihara S; Sunami E; Ushiku T; Kitayama J; Fukayama M; Kokudo N; Watanabe T
Ann Surg Oncol; 2016 Jun; 23(6):1916-23. PubMed ID: 26832881
[TBL] [Abstract][Full Text] [Related]
9. Expression of the stem cell marker CD133 is related to tumor development in colorectal carcinogenesis.
Kazama S; Kishikawa J; Kiyomatsu T; Kawai K; Nozawa H; Ishihara S; Watanabe T
Asian J Surg; 2018 May; 41(3):274-278. PubMed ID: 28190751
[TBL] [Abstract][Full Text] [Related]
10. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC
Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798
[TBL] [Abstract][Full Text] [Related]
11. Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer.
Galizia G; Gemei M; Del Vecchio L; Zamboli A; Di Noto R; Mirabelli P; Salvatore F; Castellano P; Orditura M; De Vita F; Pinto M; Pignatelli C; Lieto E
Arch Surg; 2012 Jan; 147(1):18-24. PubMed ID: 22250106
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of CD133 and ezrin expression in colorectal carcinoma.
Fathi A; Mosaad H; Hussein S; Roshdy M; Ismail EI
IUBMB Life; 2017 May; 69(5):328-340. PubMed ID: 28261953
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
[TBL] [Abstract][Full Text] [Related]
14. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients.
Takahashi S; Kamiyama T; Tomaru U; Ishizu A; Shida T; Osaka M; Sato Y; Saji Y; Ozaki M; Todo S
Oncol Rep; 2010 Nov; 24(5):1201-12. PubMed ID: 20878111
[TBL] [Abstract][Full Text] [Related]
15. Association between CD133 expression and clinicopathological profile in colorectal cancer.
Rey I; Putra A; Lindarto D; Yusuf F
Med Glas (Zenica); 2020 Aug; 17(2):402-407. PubMed ID: 32253906
[TBL] [Abstract][Full Text] [Related]
16. Colorectal Cancer: Is it Still a Disease of the Elderly?
Kędzia-Berut R; Berut M; Włodarczyk M; Włodarczyk J; Dziki Ł; Dziki A; Mik M
Pol Przegl Chir; 2023 Dec; 96(0):41-45. PubMed ID: 38348978
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Expression of CD133 and LGR5 in Ulcerative Colitis-associated Colorectal Cancer and Dysplasia.
Kazama S; Kishikawa J; Tanaka T; Hata K; Kawai K; Nozawa H; Ishihara S
In Vivo; 2019; 33(4):1279-1284. PubMed ID: 31280219
[TBL] [Abstract][Full Text] [Related]
18. Clinical Significance of Cancer Stem Cell Markers CD133 and CXCR4 in Osteosarcomas.
Mardani A; Gheytanchi E; Mousavie SH; Madjd Jabari Z; Shooshtarizadeh T
Asian Pac J Cancer Prev; 2020 Jan; 21(1):67-73. PubMed ID: 31983166
[TBL] [Abstract][Full Text] [Related]
19. Do We Underestimate Colorectal Cancer Patients Under 50?
Benli S; Colak T; Türkmenoğlu MÖ; Sari H; Baysan C
Pol Przegl Chir; 2022 May; 95(1):13-19. PubMed ID: 36806160
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of stem cell marker CD133 expression in colorectal cancer.
Wang BB; Li ZJ; Zhang FF; Hou HT; Yu JK; Li F
Histol Histopathol; 2016 Mar; 31(3):299-306. PubMed ID: 26442717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
